Select publications

Pharmacokinetics of anastrozole and tamoxifen alone and in combination during adjuvant endocrine therapy for early breast cancer in postmenopausal women: A sub-protocol of the “Arimidex® and Tamoxifen Alone or in Combination” (ATAC) trial. Br J Cancer 2001;85(3):317-324. Abstract

Baum M. The ATAC (Arimidex, Tamoxifen, Alone or in Combination) adjuvant breast cancer trial in post-menopausal women. Breast Cancer Res Treat 2001;69(3):Abstract 8.

Baum M et al. Sequential power calculations in a recruitment phase of a multicentre trial — the experience of the ‘Arimidex (anastrozole), tamoxifen alone or in combination’ (ATAC) study. Proc ASCO 2002;Abstract 185.

Brodie A. Aromatase inhibitors in breast cancer. Trends Endocr Metab 2002;13(2):61-65. Abstract

Buzdar AU. Anastrozole (Arimidex) —- an aromatase inhibitor for the adjuvant setting? Br J Cancer 2001;85(2 suppl):6-10. Abstract

Duffy SRG et al. The ATAC (‘Arimidex,’ tamoxifen, alone or in combination) early breast cancer (EBC) trial in postmenopausal (PM) patients: Endometrial sub-protocol results. Proc ASCO 2002;Abstract 158.

Fallowfield L et al. Assessing the quality of life (QOL) of postmenopausal (PM) women randomized into the ATAC (‘Arimidex,’ tamoxifen, alone or in combination) adjuvant breast cancer (BC) trial. Proc ASCO 2002;Abstract 159.

Goss PE. Preliminary data from ongoing adjuvant aromatase inhibitor trials. Clin Cancer Res 2001;7(12 suppl):4397s-4401s. Abstract